Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
- PMID: 20097417
- DOI: 10.1016/S0140-6736(09)61879-1
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
Abstract
Background: Reduced duration of antibiotic treatment might contain the emergence of multidrug-resistant bacteria in intensive care units. We aimed to establish the effectiveness of an algorithm based on the biomarker procalcitonin to reduce antibiotic exposure in this setting.
Methods: In this multicentre, prospective, parallel-group, open-label trial, we used an independent, computer-generated randomisation sequence to randomly assign patients in a 1:1 ratio to procalcitonin (n=311 patients) or control (n=319) groups; investigators were masked to assignment before, but not after, randomisation. For the procalcitonin group, antibiotics were started or stopped based on predefined cut-off ranges of procalcitonin concentrations; the control group received antibiotics according to present guidelines. Drug selection and the final decision to start or stop antibiotics were at the discretion of the physician. Patients were expected to stay in the intensive care unit for more than 3 days, had suspected bacterial infections, and were aged 18 years or older. Primary endpoints were mortality at days 28 and 60 (non-inferiority analysis), and number of days without antibiotics by day 28 (superiority analysis). Analyses were by intention to treat. The margin of non-inferiority was 10%. This trial is registered with ClinicalTrials.gov, number NCT00472667.
Findings: Nine patients were excluded from the study; 307 patients in the procalcitonin group and 314 in the control group were included in analyses. Mortality of patients in the procalcitonin group seemed to be non-inferior to those in the control group at day 28 (21.2% [65/307] vs 20.4% [64/314]; absolute difference 0.8%, 90% CI -4.6 to 6.2) and day 60 (30.0% [92/307] vs 26.1% [82/314]; 3.8%, -2.1 to 9.7). Patients in the procalcitonin group had significantly more days without antibiotics than did those in the control group (14.3 days [SD 9.1] vs 11.6 days [SD 8.2]; absolute difference 2.7 days, 95% CI 1.4 to 4.1, p<0.0001).
Interpretation: A procalcitonin-guided strategy to treat suspected bacterial infections in non-surgical patients in intensive care units could reduce antibiotic exposure and selective pressure with no apparent adverse outcomes.
Funding: Assistance Publique-Hôpitaux de Paris, France, and Brahms, Germany.
Copyright 2010 Elsevier Ltd. All rights reserved.
Comment in
-
Will procalcitonin reduce antibiotic use in intensive care?Lancet. 2010 Feb 6;375(9713):435-6. doi: 10.1016/S0140-6736(10)60140-7. Epub 2010 Jan 25. Lancet. 2010. PMID: 20097416 No abstract available.
-
Procalcitonin in intensive care units: the PRORATA trial.Lancet. 2010 May 8;375(9726):1605; author reply 1606-7. doi: 10.1016/S0140-6736(10)60695-2. Lancet. 2010. PMID: 20452513 No abstract available.
-
Procalcitonin in intensive care units: the PRORATA trial.Lancet. 2010 May 8;375(9726):1605-6; author reply 1606-7. doi: 10.1016/S0140-6736(10)60696-4. Lancet. 2010. PMID: 20452514 No abstract available.
-
Procalcitonin in intensive care units: the PRORATA trial.Lancet. 2010 May 8;375(9726):1605; author reply 1606-7. doi: 10.1016/S0140-6736(10)60694-0. Lancet. 2010. PMID: 20452515 No abstract available.
-
Procalcitonin in intensive care units: the PRORATA trial.Lancet. 2010 May 8;375(9726):1606; author reply 1606-7. doi: 10.1016/S0140-6736(10)60697-6. Lancet. 2010. PMID: 20452516 No abstract available.
-
[Management of antibiotics in regard of procalcitonin levels: PRORATA trial (PROcalcitonin to Reduce Antibiotic Treatments in Acutely ill patients)].Internist (Berl). 2010 Dec;51(12):1582-4. doi: 10.1007/s00108-010-2748-5. Internist (Berl). 2010. PMID: 21104218 German. No abstract available.
Similar articles
-
Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.Lancet Infect Dis. 2016 Jul;16(7):819-827. doi: 10.1016/S1473-3099(16)00053-0. Epub 2016 Mar 2. Lancet Infect Dis. 2016. PMID: 26947523 Clinical Trial.
-
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.Evid Based Child Health. 2013 Jul;8(4):1297-371. doi: 10.1002/ebch.1927. Evid Based Child Health. 2013. PMID: 23877944 Review.
-
Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients--calculated sample size: 1816 patients.BMC Infect Dis. 2013 Apr 16;13:178. doi: 10.1186/1471-2334-13-178. BMC Infect Dis. 2013. PMID: 23590389 Free PMC article. Clinical Trial.
-
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007498. doi: 10.1002/14651858.CD007498.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2017 Oct 12;10:CD007498. doi: 10.1002/14651858.CD007498.pub3. PMID: 22972110 Free PMC article. Updated. Review.
-
Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial.BMC Health Serv Res. 2007 Jul 5;7:102. doi: 10.1186/1472-6963-7-102. BMC Health Serv Res. 2007. PMID: 17615073 Free PMC article. Clinical Trial.
Cited by
-
Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy.Pharmaceutics. 2024 May 17;16(5):677. doi: 10.3390/pharmaceutics16050677. Pharmaceutics. 2024. PMID: 38794338 Free PMC article.
-
Evaluation of Serial Procalcitonin Levels for the Optimization of Antibiotic Use in Non-Critically Ill COVID-19 Patients.Pharmaceuticals (Basel). 2024 May 12;17(5):624. doi: 10.3390/ph17050624. Pharmaceuticals (Basel). 2024. PMID: 38794194 Free PMC article.
-
The Clinical Pulmonary Infection Score Combined with Procalcitonin and Lung Ultrasound (CPIS-PLUS), a Good Tool for Ventilator Associated Pneumonia Early Diagnosis in Pediatrics.Children (Basel). 2024 May 14;11(5):592. doi: 10.3390/children11050592. Children (Basel). 2024. PMID: 38790587 Free PMC article.
-
Role of biomarkers in antimicrobial stewardship: physicians' perspectives.Korean J Intern Med. 2024 May;39(3):413-429. doi: 10.3904/kjim.2023.558. Epub 2024 Apr 30. Korean J Intern Med. 2024. PMID: 38715231 Free PMC article.
-
[Procalcitonin: The Ideal Biomarker To Guide Initiation, Change and Withdrawal of Antibiotics in Septic Burn Patients?].Ann Burns Fire Disasters. 2023 Jun 30;36(2):125-131. eCollection 2023 Jun. Ann Burns Fire Disasters. 2023. PMID: 38681947 Free PMC article. French.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical